Skip to content

Pharminent

cropped-banner_frontpage_2026-07-11-2.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Commercial
  • Eli Lilly lifts 2026 revenue guidance as Q1 marks dominant opening
  • Commercial

Eli Lilly lifts 2026 revenue guidance as Q1 marks dominant opening

Pharmaceutical Technology

Sales for Lilly blew past expectations in the quarter as demand for weight loss treatments showed no signs of abating.

Read full story

pharminent May 1, 2026 (Last updated: May 1, 2026)

Pharmaceutical Technology

Sales for Lilly blew past expectations in the quarter as demand for weight loss treatments showed no signs of abating.

Read full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: BMS brings the buzz around late-stage readouts amid a so-so Q1
Next: LEO Pharma to acquire gene therapy company Replay

Related Stories

  • Commercial

Wegovy pill launches in UK as first daily oral GLP1 for weight management

pharminent July 6, 2026
  • Commercial

Tryngolza charts blockbuster course after FDA’s hypertriglyceridemia approval

pharminent June 26, 2026
  • Commercial

Lilly launches its LillyDirect sales channel in the UK

pharminent June 25, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.